DEEP KNOWLEDGE GROUP

Alzheimer's Global Challenge Ecosystem

Deep Knowledge Group and Aging Analytics Agency released a new report titled **"Alzheimer's Global Challenge Ecosystem 2024"** exploring the complex terrain of Alzheimer's, providing insights into its worldwide implications and the intricacies of the industry.

From examining it as a health challenge to exploring its connection with **Lyme Disease and Autism**, we delve into the latest scientific insights, epidemiological data, and the significant impact on public health. This scrutiny extends to the Alzheimer's market, offering an overview of key players, stakeholder collaborations, and market trends.

The comprehensive report thoroughly examines the challenges and opportunities inherent in the diagnosis and treatment of Alzheimer's. Notably, the involvement of celebrities, governmental initiatives, and the increasing call for collaborative efforts are all pivotal aspects explored in this detailed analysis, shedding light on the multifaceted landscape of Alzheimer's research and advocacy.

Grasping the factors that influence the prevalence of Alzheimer's is imperative for effective prevention, diagnosis, and management. Continuous research efforts, public awareness initiatives, and collaborative endeavors are pivotal in mitigating the **Alzheimer's Disease Global Health Impact.**

400+ Top Alzheimer's Clinics

3000+ Investors

3300+ Clinic Trials

25000+ Data Points

Key Takeaways

Alzheimer's Disease presents intricate challenges to public health, necessitating proactive measures. Collaborative efforts from healthcare professionals, policymakers, and the community are imperative. Exploring the possible link between increasing Lyme disease prevalence and growing Alzheimer's incidence requires comprehensive research.

Governments globally acknowledge the importance of Alzheimer's Disease and other dementia direct and indirect costs both in life quality and in billions of US dollars, and have taken proactive steps to tackle its challenges. Over 50 countries have formed parliamentary groups and governmental initiatives on Alzheimer's research.

Present Alzheimer's management focuses on symptom-based diagnosis, mostly symptomatic treatments, supportive care. Future strategies aim for early advanced diagnostics through AI based algorithms, potentially including early predictive genetic screening at the prevention stage. Advanced treatments like hyperbaric therapy, intermittent hypoxic-hyperoxic treatment, cell therapy, brain stimulation and neurofeedback techniques show promise.

Advancing research, and actively embracing cutting-edge treatment methods such as Intermittent hypoxic-hyperoxic treatment are crucial steps to mitigate the impact of the rising prevalence of Alzheimer's Disease on global health.

About Deep Knowledge Group

DEEP KNOWLEDGE GROUP

Deep Knowledge Group is a data-driven consortium of commercial and non-profit organizations active on many fronts in the realm of DeepTech and Frontier Technologies (AI, Longevity, BioTech, Pharma, FinTech, GovTech, SpaceTech, FemTech, Data Science, InvestTech), ranging from scientific research to investment, entrepreneurship, analytics, consulting, media, philanthropy and more. As a mathematical corporation dedicated to constructing the bridge to the 5th Industrial Revolution, Deep Knowledge Group is resolutely committed to DeepTech for Social Good, Techno-Philanthropy, and DeepTech.

Additionally, the company is devoted to Longevity Industry Financial Commoditization, aiming to establish the core investment and financial industry infrastructure necessary for the emergence of DeepTech and Longevity as fundamentally new asset classes.

www.dkv.global

Info@deep-knowledge.org

Global Alzheimer's Prevalence

Alzheimer's is a complex neurodevelopmental condition marked by difficulties in social communication and interaction, coupled with repetitive behaviors. Its prevalence arises from a combination of factors, including genetic susceptibilities and environmental influences. Global occurrences of Alzheimer's have been notably influenced by shifts in societal behaviors, environmental changes, and lifestyle modifications.

The estimated prevalence of Alzheimer's Disease is more than 50 million people globally. The prevalence rapidly increases with age, from 0.6% for age group 55-64 years, reaching 5% for 65-74 years and 13% for the 75 to 84 age range and surges to 33% for individuals aged 85 and above.



Prediction of the Alzheimer's Market



The global Alzheimer's treatment market is expected to witness substantial growth, climbing from USD **2.2 Billion** in 2020 to USD **13.7 Billion** in 2030, representing a robust Compound Annual Growth Rate (CAGR) of approximately **20%.**

Advancements in healthcare, driven by substantial investments from major corporations and government institutions, underscore the increasing significance of precise diagnostics and refined treatment strategies for addressing the complexities of Alzheimer's Disease. This includes providing comprehensive support across the entire spectrum, catering to individuals with mild forms of the condition.

The diagnostic market is projected to expand steadily from USD **3.3 Billion** in 2021 to USD **7.1 Billion** in 2030, emphasizing the growing demand for sophisticated diagnostic tools in the detection of Alzheimer's Disease, the focus is on achieving earlier identification and enhanced condition management. This surge is propelled by factors such as increased awareness and reporting of Alzheimer's cases, advancements in diagnostic technologies, and sustained investments in research and development for the creation of more precise and effective diagnostic tools dedicated to detecting Alzheimer's Disease.

Alzheimer's Clinical Trials

Alzheimer's research is an established and popular area for clinical research. The most significant players in the market are **Pfizer** (USA) with its subsidiary **Wyeth**, having started 91 clinical trials together, **Eli Lilly and Company** (USA) with its subsidiary **Avid Radiopharmaceuticals** (USA), with 86 clinical trials together, and **National Institute of Aging** (USA) with 40 clinical trials.

Seven companies have been sponsors for 25-30 clinical trials on ASD: **Indiana University** (USA), **GlaxoSmithKline** (UK), **John Hopkins University** (USA), **Merck Sharp & Dohme LLC** (USA), **AstraZeneca** (UK), **Centre Hospitalier Universitaire de Nice** (France), **Massachusetts General Hospital** (USA).

Most leading sponsors are thus from USA, but some significant sponsors are from UK and France.